eCQM QICore Content Subset Implementation Guide
2024.0.0 - CI Build
eCQM QICore Content Subset Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2024.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/ecqm-content-qicore-2024-subset/ and changes regularly. See the Directory of published versions
Official URL: https://madie.cms.gov/Measure/HospitalHarmHyperglycemiainHospitalizedPatientsFHIR | Version: 0.1.000 | |||
Active as of 2024-09-09 | Responsible: Centers for Medicare & Medicaid Services (CMS)/a> | Computable Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR | ||
Other Identifiers: Short Name: CMS871FHIR (use: usual, ), UUID:c44ca609-d795-4715-a8fc-1b0b30e46048 (use: official, ), UUID:c7dbf77f-5869-42a0-b5e6-12e18004d2f4 (use: official, ), Endorser: 3533e (use: official, ), Publisher: 871FHIR (use: official, ) | ||||
Usage:Venue: EH |
||||
Copyright/Legal: Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. American Institutes for Research(R), formerly IMPAQ International, disclaims all liability for use or accuracy of any third party codes contained in the specifications. LOINC(R) copyright 2004-2023 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2023 International Health Terminology Standards Development Organisation. ICD-10 copyright 2023 World Health Organization. All Rights Reserved. |
Knowledge Artifact Metadata | |
---|---|
Name (machine-readable) | HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
Title (human-readable) | Hospital Harm - Severe HyperglycemiaFHIR |
Status | Active |
Experimental | false |
Description | This measure assesses the number of inpatient hospital days for patients age 18 and older with a hyperglycemic event (harm) per the total qualifying inpatient hospital days for that encounter |
Purpose | UNKNOWN |
Clinical Usage | The measure is using mg/dL as the unit of measurement for glucose results. When evaluating for days with a glucose level >300 mg/dL, the first 24-hour period after admission to the hospital is not evaluated to account for potentially poor glucose control outside of the hospital setting or that preceded the start of hospital care. The admission starts in the emergency department (ED) or observation when the transition between the ED encounter, observation encounter, and the inpatient encounter are within an hour or less of each other. This measure evaluates the first 10 days of an eligible inpatient hospitalization in determining eligible days for the denominator and numerator (i.e., the length of stay is truncated to <=10 days when the length exceeds 10 days). Patients admitted for longer length of stays are more likely to have more complex medical conditions. The “Days in Hospitalization” logic within Measure Observation 1 (associated with the denominator), in conjunction with other logic, returns the day number (e.g., day 1 to day 10) for each day within the hospitalization period to determine the eligible hospital days (e.g., from day 2 to day 10). The “Days in Hospitalization” logic within Measure Observation 2 (associated with the numerator), in conjunction with other logic, returns the day number (e.g., day 1 to day 10) for each day within the hospitalization period to determine the eligible hyperglycemic event days (e.g., from day 2 to day 10). Since the measure does not count any hyperglycemic events that occur in the first 24 hours, day 1 is not considered an eligible hospital day for the Measure Observations. Eligible days range from day 2 up to day 10. Although the measure does not count any hyperglycemic events that occur in the first 24 hours as a hyperglycemic event day in Measure Observation 2, the first 24 hours of the encounter is considered day 1. This is because if there was a day during the encounter where a glucose result is not found, the measure evaluates the two days preceding to see if each had a glucose value >=200 mg/dL. The measure allows the first 24 hours of the encounter, i.e., day 1, to be one of the preceding days. Multiple hyperglycemic events can occur during a ‘day’, but this is still considered one hyperglycemic event day. The numerator returns the first eligible encounter that meets the qualifying criteria: an inpatient hospitalization with a hyperglycemic event. Only one numerator is counted per encounter. Note that the Numerator returns the encounters, not days, that meet the criteria. The specimen source for the glucose test is blood, serum, plasma, or interstitial fluid, and can be obtained by a laboratory test, a Point of Care (POC) test, or a continuous glucose monitor (CGM). Glucose test results from urine specimens are not considered. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This FHIR-based measure has been derived from the QDM-based measure: CMS871v4. Please refer to the HL7 QI-Core Implementation Guide(https://hl7.org/fhir/us/qicore/STU4.1.1/) for more information on QI-Core and mapping recommendations from QDM to QI-Core4.1.1 (https://hl7.org/fhir/us/qicore/STU4.1.1/qdm-to-qicore.html). |
Effective Period | 2025-01-01..2025-12-31 |
Use Context | Venue = EH |
Measure Developer | American Institutes for Research (AIR): https://www.air.org |
Measure Steward | Centers for Medicare & Medicaid Services (CMS) |
Steward Contact Details | https://www.cms.gov/ |
Copyright | Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. American Institutes for Research(R), formerly IMPAQ International, disclaims all liability for use or accuracy of any third party codes contained in the specifications. LOINC(R) copyright 2004-2023 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2023 International Health Terminology Standards Development Organisation. ICD-10 copyright 2023 World Health Organization. All Rights Reserved. |
Measure Metadata | |
Short Name Identifier | CMS871FHIR |
Version Independent Identifier | urn:uuid:c44ca609-d795-4715-a8fc-1b0b30e46048 |
Version Specific Identifier | urn:uuid:c7dbf77f-5869-42a0-b5e6-12e18004d2f4 |
Publisher (CMS) Identifier | 871FHIR |
Identifier | Endorser/3533e (use: official, ) |
Version Number | 0.1.000 |
Measure Scoring | Ratio |
Rationale | Hyperglycemia, i.e., elevated glucose level, is common among hospitalized patients, especially those with preexisting diabetes (Umpierrez et al., 2012) and account for over 30% of noncritically ill hospitalized patients (Korytkowski, 2022). Hyperglycemia can also affect individuals with no prior history of diabetes and may be induced by medications such as steroids, or parenteral (intravenous) or enteral (tube) feeding. Severe hyperglycemia, i.e., extremely elevated glucose level, is significantly associated with a range of harms, including increased in-hospital mortality, infection rates, and hospital length of stay (Pasquel, et al., 2021; Umpierrez et al., 2012, 2015). Lower rates of inpatient severe hyperglycemia may not only improve care for patients, but also reduce costs for healthcare payers (Krinsley et al., 2016). The rate of hyperglycemia varies across hospitals, suggesting opportunities for improvement in inpatient glycemic management (Seisa et al., 2022; Bersoux et al., 2013). The rate of inpatient hyperglycemia can be considered a marker for quality of hospital care, since inpatient hyperglycemia is largely avoidable with proper glycemic management. The use of evidence-based standardized protocols and insulin management protocols have been shown to improve glycemic control and safety (Leroy et al., 2020; Maynard et al., 2015). From the Endocrine Society clinical practice guideline on the Management of Hyperglycemia in Hospitalized Patients in Non-critical Care Setting, 2022: Recommendation 1.1 In adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia, we suggest the use of real-time continuous glucose monitoring (CGM) with confirmatory bedside point-of-care blood glucose (POC-BG) monitoring for adjustments in insulin dosing rather than point-of-care blood glucose (POC-BG) testing alone in hospital settings where resources and training are available. |
Clinical Recommendation Statement | Multiple guidelines address recommended levels of glycemic control, though these do not define severe hyperglycemia: From Section 16, Diabetes Care in the Hospital, in the Standards of Medical Care in Diabetes by the American Diabetes Association, (American Diabetes Association, 2023): 16.4 Insulin therapy should be initiated for the treatment of persistent hyperglycemia starting at a threshold ≥180 mg/dL (10.0 mmol/L) (checked on two occasions). Once insulin therapy is started, a target glucose range of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for most critically ill and noncritically ill patients. 16.5 More stringent goals, such as 110–140 mg/dL (6.1–7.8 mmol/L) or 100–180 mg/dL (5.6–10.0 mmol/L), may be appropriate for selected patients and are acceptable if they can be achieved without significant hypoglycemia. From the Endocrine Society clinical practice guideline on the Management of Hyperglycemia in Hospitalized Patients in Non-critical Care Setting (2022): Recommendation 10.1 In adults with no prior history of diabetes hospitalized for noncritical illness with hyperglycemia [defined as blood glucose (BG) > 140 mg/dL (7.8 mmol/L)] during hospitalization, we suggest initial therapy with correctional insulin over scheduled insulin therapy (defined as basal or basal/bolus insulin) to maintain glucose targets in the range of 100 to 180 mg/dL (5.6 to 10.0 mmol/L). For patients with persistent hyperglycemia [≥2 point-of-care blood glucose (POC-BG) measurements ≥ 180 mg/dL (≥10.0 mmol/L) in a 24-hour period on correctional insulin alone], we suggest the addition of scheduled insulin therapy. Recommendation 10.2 In adults with diabetes treated with diet or noninsulin diabetes medications prior to admission, we suggest initial therapy with correctional insulin or scheduled insulin therapy to maintain glucose targets in the range of 100 to 180 mg/dL (5.6 to 10.0 mmol/L). For hospitalized adults started on correctional insulin alone and with persistent hyperglycemia [≥2 point-of-care blood glucose (POC-BG) measurements ≥ 180 mg/dL in a 24-hour period (≥10.0 mmol/L)], we suggest addition of scheduled insulin therapy. We suggest initiation of scheduled insulin therapy for patients with confirmed admission blood glucose (BG) ≥ 180 mg/dL (≥10.0 mmol/L). Recommendation 10.3 In adults with insulin-treated diabetes prior to admission who are hospitalized for noncritical illness, we recommend continuation of the scheduled insulin regimen modified for nutritional status and severity of illness to maintain glucose targets in the range of 100 to 180 mg/dL (5.6 to 10.0 mmol/L). Remarks Reductions in the dose of basal insulin (by 10% to 20%) at time of hospitalization may be required for patients on basal heavy insulin regimens (defined as doses of basal insulin ≥ 0.6 to 1.0 units/kg/day), in which basal insulin is being used inappropriately to cover meal-related excursions in BG. There is no clinically accepted cutoff for severe hyperglycemia. Studies have used thresholds of >140, >180 , >300, >350 and >400 mg/dL, among other values (American Diabetes Association, 2023; Umpierrez et al, 2012, 2015; Jamesen et al., 2015; Donihi et al., 2011; Mendez et al, 2015; Seisa et al., 2022). BGL <180 mg/dL is associated with lower rates of mortality and stroke compared with a target glucose <200 mg/dL (Sathya et al., 2013). Glycemic goals may also differ among hospitalized patients. For inpatient management of hyperglycemia in noncritical care, the expert consensus recommends a target range of 100–180 mg/dL (5.6–10.0 mmol/L) for noncritically ill patients with “new” hyperglycemia as well as people with known diabetes prior to admission. Glycemic levels >250 mg/dL (13.9 mmol/L) may be acceptable in terminally ill patients with short life expectancy. In these individuals, less aggressive insulin regimens to minimize glucosuria, dehydration, and electrolyte disturbances are often more appropriate. (ElSayed et al., 2023). In an older patient with a prior history of severe hypoglycemia, some degree of hyperglycemia may be tolerated to maximize safety. Intensive insulin therapy to target glucose of 100 and 140mg/dLin the ICU didn’t significantly reduce perioperative complications compared with target glucose of 141and180mg/dL after coronary artery bypass surgery (Umpierrez et al., 2015). The current recommendation is to maintain a blood glucose level between 140-180 mg/dL (7.8-10.0 mmol/L) in both cardiac and non-cardiac ICU patients (Sreedharan et al., 2022). For patients who present with hyperglycemic crises, neurologic status must be monitored closely, with frequent re-examination. Care should be taken to prevent over-correction of hyperglycemia and hyperosmolarity following initial fluid resuscitation of these patients to prevent cerebral edema, which carries a high mortality rate. (Gosmanov et al., 2021). From the Endocrine Society clinical practice guideline on the Management of Hyperglycemia in Hospitalized Patients in Non-critical Care Setting, 2022: Recommendation 1.1 In adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia, we suggest the use of real-time continuous glucose monitoring (CGM) with confirmatory bedside point-of-care blood glucose (POC-BG) monitoring for adjustments in insulin dosing rather than point-of-care blood glucose (POC-BG) testing alone in hospital settings where resources and training are available. |
Guidance | The measure is using mg/dL as the unit of measurement for glucose results. When evaluating for days with a glucose level >300 mg/dL, the first 24-hour period after admission to the hospital is not evaluated to account for potentially poor glucose control outside of the hospital setting or that preceded the start of hospital care. The admission starts in the emergency department (ED) or observation when the transition between the ED encounter, observation encounter, and the inpatient encounter are within an hour or less of each other. This measure evaluates the first 10 days of an eligible inpatient hospitalization in determining eligible days for the denominator and numerator (i.e., the length of stay is truncated to <=10 days when the length exceeds 10 days). Patients admitted for longer length of stays are more likely to have more complex medical conditions. The “Days in Hospitalization” logic within Measure Observation 1 (associated with the denominator), in conjunction with other logic, returns the day number (e.g., day 1 to day 10) for each day within the hospitalization period to determine the eligible hospital days (e.g., from day 2 to day 10). The “Days in Hospitalization” logic within Measure Observation 2 (associated with the numerator), in conjunction with other logic, returns the day number (e.g., day 1 to day 10) for each day within the hospitalization period to determine the eligible hyperglycemic event days (e.g., from day 2 to day 10). Since the measure does not count any hyperglycemic events that occur in the first 24 hours, day 1 is not considered an eligible hospital day for the Measure Observations. Eligible days range from day 2 up to day 10. Although the measure does not count any hyperglycemic events that occur in the first 24 hours as a hyperglycemic event day in Measure Observation 2, the first 24 hours of the encounter is considered day 1. This is because if there was a day during the encounter where a glucose result is not found, the measure evaluates the two days preceding to see if each had a glucose value >=200 mg/dL. The measure allows the first 24 hours of the encounter, i.e., day 1, to be one of the preceding days. Multiple hyperglycemic events can occur during a ‘day’, but this is still considered one hyperglycemic event day. The numerator returns the first eligible encounter that meets the qualifying criteria: an inpatient hospitalization with a hyperglycemic event. Only one numerator is counted per encounter. Note that the Numerator returns the encounters, not days, that meet the criteria. The specimen source for the glucose test is blood, serum, plasma, or interstitial fluid, and can be obtained by a laboratory test, a Point of Care (POC) test, or a continuous glucose monitor (CGM). Glucose test results from urine specimens are not considered. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This FHIR-based measure has been derived from the QDM-based measure: CMS871v4. Please refer to the HL7 QI-Core Implementation Guide(https://hl7.org/fhir/us/qicore/STU4.1.1/) for more information on QI-Core and mapping recommendations from QDM to QI-Core4.1.1 (https://hl7.org/fhir/us/qicore/STU4.1.1/qdm-to-qicore.html). |
Supplemental Data Guidance | For every patient evaluated by this measure also identify payer, race, ethnicity and sex; SDE Ethnicity SDE Payer SDE Race SDE Sex |
Measure Population Criteria (ID: 6501fe8dda013638e7b3dc0d) | |
Initial Population |
ID: 9B922C53-7F1B-4AF5-96E6-1A1E4AF7909C
Description: Inpatient hospitalizations for patients age 18 and older that end during the measurement period, as well as either: - A diagnosis of diabetes that starts before or during the encounter; or - Administration of at least one dose of insulin or any hypoglycemic medication during the encounter; or - Presence of at least one glucose value >=200 mg/dL at any time during the encounter Logic Definition: Initial Population |
Denominator |
ID: 6402512C-2305-42DC-B5F6-A226B5057B89
Description: Equals Initial Population Logic Definition: Denominator |
Denominator Exclusion |
ID: 0F4405D3-B373-4620-A9CC-D29558C39E85
Description: -Inpatient hospitalizations for patients with a glucose result of >=1000 mg/dL anytime between 1 hour prior to the start of the encounter to 6 hours after the start of the encounter -Inpatient hospitalizations for patients who have comfort care measures ordered or provided during the encounter -Inpatient hospitalizations for patients who have a discharge disposition to home or to a health care facility for hospice care Logic Definition: Denominator Exclusions |
Numerator |
ID: 340EA45E-2411-4192-9C9D-3DF8D89A1D97
Description: Inpatient hospitalizations with a hyperglycemic event within the first 10 days of the encounter minus the first 24 hours, and minus the last period before discharge from the hospital if less than 24 hours A hyperglycemic event is defined as: - A day with at least one glucose value >300 mg/dL; OR - A day where a glucose test and result was not found, and it was preceded by two consecutive days where at least one glucose value during each of the two days was >=200 mg/dL Logic Definition: Numerator |
Measure Observation |
ID: 68900484-66a1-4da3-9b02-1a10a5fd592b
Description: No description provided Logic Definition: Denominator Observations |
Measure Observation |
ID: f1bc37e5-f64f-4ed8-b965-2011f1181225
Description: No description provided Logic Definition: Numerator Observations |
Population Basis | Encounter |
Scoring | Ratio |
Type | Outcome |
Rate Aggregation | None |
Improvement Notation | decrease |
Supplemental Data Elements | |
Supplemental Data Element |
ID: sde-ethnicity
Usage Code: Supplemental Data Description: SDE Ethnicity Logic Definition: SDE Ethnicity |
Supplemental Data Element |
ID: sde-payer
Usage Code: Supplemental Data Description: SDE Payer Logic Definition: SDE Payer |
Supplemental Data Element |
ID: sde-race
Usage Code: Supplemental Data Description: SDE Race Logic Definition: SDE Race |
Supplemental Data Element |
ID: sde-sex
Usage Code: Supplemental Data Description: SDE Sex Logic Definition: SDE Sex |
Measure Logic | |
Primary Library | HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
Dependency |
Description: Library SDE
Resource: Library/SupplementalDataElements|3.5.000
Canonical URL: Library/SupplementalDataElements|3.5.000 |
Dependency |
Description: Library FHIRHelpers
Resource: Library/FHIRHelpers|4.4.000
Canonical URL: Library/FHIRHelpers|4.4.000 |
Dependency |
Description: Library CQMCommon
Resource: Library/CQMCommon|2.2.000
Canonical URL: Library/CQMCommon|2.2.000 |
Dependency |
Description: Library QICoreCommon
Resource: Library/QICoreCommon|2.1.000
Canonical URL: Library/QICoreCommon|2.1.000 |
Dependency |
Description: Code system AdministrativeGender
Resource: AdministrativeGender Canonical URL: http://hl7.org/fhir/administrative-gender |
Dependency |
Description: Value set Encounter Inpatient
Resource: Encounter Inpatient Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 |
Dependency |
Description: Value set Observation Services
Resource: Observation Services Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143 |
Dependency |
Description: Value set Emergency Department Visit
Resource: Emergency Department Visit Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 |
Dependency |
Description: Value set Diabetes
Resource: Diabetes Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 |
Dependency |
Description: Value set Hypoglycemics Treatment Medications
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394 |
Dependency |
Description: Value set Glucose Lab Test Mass Per Volume
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 |
Dependency |
Description: Value set Payer Type
Resource: Payer Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Direct Reference Code |
Display: Male
Code: M System: http://hl7.org/fhir/administrative-gender |
Direct Reference Code |
Display: Female
Code: F System: http://hl7.org/fhir/administrative-gender |
Parameter |
Name: Measurement Period
Use: In Min Cardinality: 0 Max Cardinality: 1 Type: Period |
Parameter |
Name: SDE Sex
Use: Out Min Cardinality: 0 Max Cardinality: 1 Type: Coding |
Parameter |
Name: Numerator
Use: Out Min Cardinality: 0 Max Cardinality: * Type: Resource |
Parameter |
Name: Denominator
Use: Out Min Cardinality: 0 Max Cardinality: * Type: Resource |
Parameter |
Name: SDE Payer
Use: Out Min Cardinality: 0 Max Cardinality: * Type: Resource |
Parameter |
Name: Initial Population
Use: Out Min Cardinality: 0 Max Cardinality: * Type: Resource |
Parameter |
Name: SDE Ethnicity
Use: Out Min Cardinality: 0 Max Cardinality: 1 Type: Resource |
Parameter |
Name: Denominator Exclusions
Use: Out Min Cardinality: 0 Max Cardinality: * Type: Resource |
Parameter |
Name: SDE Race
Use: Out Min Cardinality: 0 Max Cardinality: 1 Type: Resource |
Measure Logic Data Requirements | |
Data Requirement |
Type: Patient
Profile(s): QICorePatient Must Support Elements: ethnicity, race |
Data Requirement |
Type: Encounter
Profile(s): QICoreEncounter Must Support Elements: type, status, status.value, period Code Filter(s): Path: type ValueSet: Observation Services Path: status.value Code: |
Data Requirement |
Type: Encounter
Profile(s): QICoreEncounter Must Support Elements: type, status, status.value, period Code Filter(s): Path: type ValueSet: Emergency Department Visit Path: status.value Code: |
Data Requirement |
Type: Encounter
Profile(s): QICoreEncounter Must Support Elements: type, period, status, status.value, hospitalizationPeriod, encounter Code Filter(s): Path: type ValueSet: Encounter Inpatient Path: status.value Code: |
Data Requirement |
Type: Condition
Profile(s): QICoreCondition Must Support Elements: code Code Filter(s): Path: code ValueSet: Diabetes |
Data Requirement |
Type: MedicationAdministration
Profile(s): QICoreMedicationAdministration Must Support Elements: medication, status, status.value, effective Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394 |
Data Requirement |
Type: Observation
Profile(s): QICoreObservation Must Support Elements: code, effective, status, status.value, value, id, id.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 Path: status.value Code: |
Data Requirement |
Type: Observation
Profile(s): QICoreObservation Must Support Elements: code, effective, value, status, status.value, id, id.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 |
Data Requirement |
Type: Coverage
Profile(s): QICoreCoverage Must Support Elements: type, period Code Filter(s): Path: type ValueSet: Payer |
Measure Logic Definitions | |
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: HospitalHarmHyperglycemiainHospitalizedPatientsFHIR |
|
|
Generated using version 0.4.6 of the sample-content-ig Liquid templates |